Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 February 2025 | Story Anthony Mthembu | Photo Kaleidoscope Studios
G20 - 2025
G20 delegates from member countries and other invited guests in attendance at the G20 Research and Innovation Working Group (RIWG) and G20 Initiative on Bioeconomy (GIB) meetings and other side events.

Against the backdrop of the upcoming G20 Summit to be hosted by South Africa in November 2025, the University of the Free State (UFS) – in partnership with the Department of Science, Technology and Innovation (DSTI) – held the G20 Research and Innovation Working Group (RIWG) and G20 Initiative on Bioeconomy (GIB) meetings on 23 and 24 February 2025.

In her opening address to G20 delegates from member countries, national and international knowledge partners, members of the Free State provincial government, and representatives of the DSTI, Prof Hester Klopper, Vice-Chancellor and Principal of the UFS, indicated, “It is an honour for the UFS to be among the few South African universities to host this essential Research and Innovation Working Group.” In addition, she highlighted that the deliberations and discussions set to take place during this important workshop can set in motion chains of events ultimately contributing to improved lives for everyone. These sentiments were also echoed by Prof Blade Nzimande, Minister of Science, Technology and Innovation, who underscored the importance and historic nature of the upcoming G20 Summit.

In his virtual address, Minister Nzimande explained that South Africa’s chosen theme for the G20 Summit – Solidarity, Equality and Sustainability – was inspired by the general complexity of our time, “in particular the transnational nature of these complexities, such as conflict, the displacement of people, poverty”, among other things. As such, he expressed that in this case, cooperation among nations is becoming increasingly essential.

As they concluded their addresses, Prof Nzimande and Prof Klopper, wished the delegates well in their deliberations. ‘’May your discussions be successful, and your goals be achieved. And may your time with us lead to a renewed experience of the value of innovation through connection, ‘’expressed Prof Klopper.

 

Contributing events

As part of the programme at these proceedings, several side events took place. These included panel discussions with indigenous knowledge holders such as Telle Hoeses, Chief Language Practitioner for Khoi and San Languages, along with experts of indigenous medicine. The conversation focused on indigenous knowledge systems (IKS) and some of the key concerns and progress that these knowledge holders have made in the space. In addition, these knowledge holders, many of whom are business owners who sell products made from indigenous medicines, also had the opportunity to exhibit their products. According to Dan du Toit, Deputy Director-General: International Cooperation and Resources at the DSTI, these panel discussions with young people, bioeconomy researchers, and indigenous knowledge holders were an opportunity to gain access to a diversity of voices, which would not normally find expression in formal meetings. “It is also an opportunity for our international guests to get insight into who we are as a country and what some of our concerns might be,” said Du Toit.

One of the highly anticipated side events on the programme was the joint G20 RIWG and GIB event titled ‘UNESCO Women and Girls in Science’, which took place on 25 February 2025. The event took the form of a round-table discussion, in an attempt to answer the question: Based on your experiences in various roles within higher education in South Africa, Africa, and globally, what are some key insights regarding the role of universities in closing the gender gap in STEM, specifically concerning professional development and creating supportive research environments where everyone, especially women, can thrive?

Prof Anthea Rhoda; Deputy Vice-Chancellor: Academic at the UFS, was one of the contributors in this session. In response to the question, Prof Rhoda highlighted, “Universities should also be spaces characterised by intellectual freedom and freedom of expression, where archaic ideas about male superiority and patriarchy can be openly confronted and contested, without fear of victimisation. She expressed that an active way in which the UFS has committed itself to a culture of diversity and inclusion is through Vision130.

As she was wrapping up her address, Prof Rhoda also highlighted, “To address areas of underrepresentation of women in senior academic and leadership positions within the university, a Working Group on Gender Parity in Academic Leadership was established, with the critical mandate to drive attitudinal shifts, advocate for changes where necessary, and highlight barriers to women’s advancement.”

 

The programme comes to an end

The last day of the programme was reserved for comments, reflections, and discussions on deliverables. As such, there were positive responses to the way the deliberations took place. In fact, Hoese, speaking in her capacity as an indigenous knowledge holder, said, “This was a good platform for us to make progress towards language recognition and officialisation.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept